Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up6.600 +0.080 (+1.227%)
Others

10/03/2021 11:11

CSPC Pharma (01093) unit signs product licensing agreement

[ET Net News Agency, 10 March 2021] CSPC Pharmaceutical Group Limited (01093) said its
subsidiary CSPC Pharmaceutical (Shanghai) Company Ltd. (CSPC Shanghai) has entered into a
product licensing and commercialization agreement with Beta Pharma (Shanghai) Company
Limited (Beta Pharma) in relation to the exclusive product licensing and commercialization
of BPI-7711 capsules, a third generation irreversible EGFR-TKI for the treatment of
non-small cell lung cancer.
CSPC Shanghai shall be granted the exclusive rights for commercialization of BPI-7711
capsules in the People's Republic of China and shall have the right of first negotiation
on licensing of commercialization of BPI-1178 Capsules (a CDK 4/6 inhibitor). (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.